129823520589843750_129Hisun pharmaceutical industry: sea is Pfizer's formal signing of the joint venture agreement
Sea is officially signed a joint venture agreement today Pfizer said Pfizer and company and wholly-owned subsidiary of sea-is Hangzhou Luxembourg company formally signed the agreement on joint venture, funded three parties will work together to set up a joint venture company
view my site here, investment amounted to US $ 295 million, registered capital of US $ 250 million. Sea is working with Pfizer and 51% of the registered capital. Sea is PfizerAlliance to promote orderly sea working with Pfizer intends to set up a joint venture company in May 2011, signed a letter of intent, a year or so to complete a formal cooperation agreement. The establishment of the joint venture company to be adopted by the Board of Trustees considered submitted to the approval of the general meeting of shareholders, and by the Department of Commerce and the national development and Reform Commission approved before the formal implementation. We believe that the joint venture company by only a matter of time, the year is expected toComplete the formation of the marketing team and variety into the integration of existing preparations, next year is expected to bring performance to the company contribution, 14 are expected to achieve greater growth. Antineoplastic agents is a joint-venture company is most likely in the early cooperation by sea are compared with the Pfizer drug product line in 2010 and raise investment projects non-public offering of shares
http://www.powerleveling.us/diablo-3, we believe that the initial anti-cancer drugs will beThe best starting point. Raised investment projects of water for injection 25 million bottles, lyophilized 25 million bottles, 160 million particles of solid preparation production line anti-tumor agents will ensure high-quality supply. Parties are expected to venture further into the future outstanding variety. Investment recommendations and ratings and the world's largest multinational enterprises and occupied a dominant position proved the companyWas highly recognized. Manufacturers while the first quarter of the year because the downstream preparation equipment maintenance to bring a certain amount of fluctuation of short-term results, but our long-term bullish on transformation from raw materials to the preparations of the company success. EPS is expected 2012-2014 $ 1.10/1.48/1.87, respectively, corresponds to current price earnings ratio twenty three-seventeenths/three times, respectively. To give2012 PE, target price $ 33, maintaining a "buy" rating. Pfizer venture and risk integration risks; Government departments approval and risk can be passed by the General Assembly of shareholders; price risks associated with prescription drug policy; drug export exchange rate risk.
